Call for Abstracts: New Zealand Applied Neurosciences Conference (NZANC) 2016

The fourth biennial New Zealand Applied Neurosciences Conference (NZANC) will be held on the 24-26 November 2016 at AUT city campus in Auckland, New Zealand.

This conference aims to and bridge the gap between epidemiological, clinical and translational neuroscience to reduce the burden of neurological disorders in New Zealand and internationally.

NZANC 2016 will showcase world-leading research from throughout New Zealand and the world. The conference will provide a blueprint and way forward for the prevention, treatment and amelioration of neurological disorders.

Date: Thursday 24 November – Saturday 26 November.

Location: AUT City Campus, Auckland.



Topics for submission

The main topics that will be presented and discussed at NZANC 2016 are as follows:

1. Basic Neuroscience

2. Clinical Neuroscience and Neurorehabilitation Research

3. Population and Health Economic Research of Neurological Disorders

Deadline abstract submission has now been extended: 2nd of September

Submit an abstract now

Brain Research New Zealand – Rangahau Roro Aotearoa (BRNZ) Symposium at NZANC 2016

For the first time, Brain Research New Zealand – Rangahau Roro Aotearoa (BRNZ) will sponsor a symposium at NZANC 2016.

This symposium will focus on our nascent national network of Dementia Prevention Research clinics. A New Zealand first, the DPRC network offers a promising way forward for interventions relating to MCI and dementia. At the symposium, BRNZ’s researchers and clinicians will outline progress made into longitudinal and intervention studies relating to dementia, particularly Alzheimer’s disease.

Additionally, highly esteemed National Science Challenge, Ageing Well will present their own fascinating symposium at the NZANC conference.

Early bird tickets for the conference are available now

Deadline for early bird tickets:  Friday 9 September.  

All accepted abstracts of registered conference participants will be published in Neuroepidemiology journal.

International speakers

BRNZ_NZANC Perminder-Sachdev
BRNZ Keynote speaker: Professor Perminder Sachdev

BRNZ Keynote speaker: Professor Perminder Sachdev 

Title: Can we really prevent Alzheimer’s dementia: Examining the evidence

Speaker: Perminder Sachdev MD PhD FRANZCP, Scientia Professor of Neuropsychiatry & Co-Director, Centre for Healthy Brain Ageing (CHeBA), University of New South Wales, Sydney, Australia.


With the rapid increase in the health burden of dementia globally, there is an urgent need to develop and implement strategies to prevent dementia and/or postpone its onset.  In the absence of effective pharmacological interventions for primary prevention, the focus has shifted to lifestyle and vascular risk factors.  The modifiable risk factors identified in the literature include vascular factors (hypertension, diabetes, atherosclerosis, high cholesterol, mid-life obesity, smoking), low brain reserve (low education, complex mental activity or physical activity and poor social network), nutritional factors (low intake of antioxidants, high homocysteine, high alcohol use) and other (depression and head injury). 

The quality of evidence for these factors is varied, with most evidence being obtained from case control and observational cohort studies.  Only some factors have been subjected to randomised control trials.  The basic science evidence is not always consistent. 

There have been some recent large intervention trials for preventing cognitive decline. There is also emerging evidence that the incidence of dementia may be declining in some high income countries. 

This talk will examine some of the available evidence, identify the gaps in the literature and suggest a way forward.  It will also ask the question whether observational evidence is sufficient to support large scale investment in interventions.  

Call for Abstracts: New Zealand Applied Neurosciences Conference (NZANC) 2016
Call for Abstracts: New Zealand Applied Neurosciences Conference (NZANC) 2016

Download the flyer 

Professor Bo Norrving

Lund University, Sweden

Bo Norrving is professor in neurology at Lund University, Sweden. His research activities have focused on stroke epidemiology, stroke syndromes, small vessel disease, ultrasound, neuroimaging, clinical genetics, clinical trials and organisation of stroke services. He was corresponding author of the Swedish Aspirin Low-Dose Trial (SALT) published in The Lancet 1991 as the first trial to demon

strate the benefit of low dose aspirin therapy for the prevention of stroke. The SALT data were also used almost 2 decades later to demonstrate that aspirin had a protective effect on colorectal cancers. He is chair of the steering committee of SIFAP, the world’s largest study on stroke in the young, and has been involved in a large number of seminal clinical trials. He is member of the Global Burden of Disease group of scientists. He has contributed to >300 articles in peer-reviewed medical journals, and has authored or co-authored several books, including The Oxford Textbook on Stroke and Cerebrovascular Diseases.

He was a European Editor of Stroke 2005 to 2010 followed by a Senior Consulting Editor position till 2015. He is the 1st the Editor-in-Chief of the European Stroke Journal founded 2016 by the European Stroke Organization.

He is a founder and current chair of Riskstroke, the world’s 1st national stroke registry, and a stroke register prototype on which many other international registers have been built.

He is member of the neurology advisory group, and chairs the cerebrovascular group, for the ICD-11 at the World Health Organisation, in which all cerebrovascular diseases now form a single block (with diseases of the nervous system as primary parent).

Bo Norrving has played an important leadership role in raising the profile of stroke globally. He was President of the World Stroke Organisation (WSO) from 2008 to 2012, and continues as executive officer through to 2016. Under his term as President, WSO underwent a phase of substantial expansion and extension of activities, including involvement with governmental bodies such as the WHO, the UN ECOSOC, and representing stroke at several high level meetings. He chairs the WSO Global Policy Committee, co-chairs the WSO Guidelines and Quality Committee, and co-authored the first WSO global guidelines for stroke under the auspices of the WSO.


Dr George Mensah

NHLBI, NIH, United States

Dr. George Mensah is a senior advisor in the Office of the Director at the National Heart, Lung, and Blood Institute (NHLBI), part of the National Institutes of Health (NIH). He also serves as Director of the Center for Translation Research and Implementation Science (CTRIS).  In this position, Dr. Mensah leads a trans-NHLBI effort to advance late-stage translational research in heart, lung, and blood diseases and sleep disorders.

Dr. Mensah’s primary focus is the application of T4 translation research and implementation science approaches to address gaps in the prevention and treatment of heart, lung, and blood diseases and the elimination of health inequities.  His goal is to maximize the population health impact of investments made in fundamental discovery science and pre-clinical or early-stage translational research in heart, lung, and blood diseases.

Dr. Mensah is a clinician-scientist trained in internal medicine and the subspecialty of cardiovascular diseases.  His professional experience includes 17 years of public service between the U.S. Department of Veterans Affairs (VA) and the Centers for Disease Control and Prevention (CDC).  He has had management experience as a chief of cardiology; head of a clinical care department; and the Surgeon General’s nominee to the Board of Governors of the American College of Cardiology as governor for public health.

In addition to his public service at CDC, Dr. Mensah had 15 years of experience in direct patient care, teaching, and research at Cornell University Medical Center, Vanderbilt University Medical Center, and the Medical College of Georgia (MCG).  He was a professor with tenure at MCG, director of the medical specialties practice at the MCG Hospitals & Clinics, and department head of cardiovascular care at the VA Medical Center in Augusta, Georgia. He holds a merit of proficiency from the American Society of Echocardiography and has been designated a “hypertension specialist” by the American Society of Hypertension. He holds fellowships in several medical societies in Africa and the US.